- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Breast cancer
- Meeting Date: November 2021
- Public Summary Document (PSD) November 2021 PBAC Meeting - (PDF 1641KB)
- Public Summary Document (PSD) November 2021 PBAC Meeting - (Word 602KB)
Sacituzumab govitecan – November 2021
Sacituzumab govitecan: Powder for injection 180 mg; Trodelvy®
Last updated
18 March 2022